Psoriatic Arthritis

New pooled data from DISCOVER-1 and DISCOVER-2 show the injection biologic provided full resolution of dactylitis in three-fourths of patients by week 52.

A cohort analysis from Norway suggests women with active psoriatic arthritis or axial spondylitis are at greater risk of either elective or emergency delivery procedures.

Radiographic non-progressors treated with guselkumab achieved patient-reported minimal disease activity criteria of minimal pain and normalized physical function more often than radiographic non-responders.

Study results are the first to demonstrate that tofacitinib may be an effective treatment option for Chinese patients with active psoriatic arthritis.

Roy Fleischmann, MD, examined the necessity of performing repeated x-rays in patients with rheumatic disease as a part of disease management.

Guselkumab, an interleukin-23 inhibitor, demonstrated sustained improvements in both TNF-naïve and TNF-experienced patients with psoriatic arthritis.

Pain, a key issue for patients with rheumatic diseases, is generally ranked as one of the top complaints of disease experience.

Philip Mease, MD, discusses other factors, besides drug inefficacy, that may impact pain in patients with rheumatic and autoimmune conditions.

In this Q&A, Rubén Queiro, MD, PhD, discussed the findings of a study that evaluated the retention rate and safety of ixekizumab in patients with psoriatic arthritis in real clinical practice conditions.

While high-sensitive Troponin T (hsTnT) is primarily used as a marker of heart disease, data suggests its potential as a useful marker of inflammation in the joints.

Patients receiving guselkumab reported significant improvements in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores over 36 months.

Electronic patient-reported outcome (ePRO) questionnaires may allow rheumatologists to better understand the patient's experience and monitor improvements over time.

Adult patients with psoriatic arthritis starting a second-line biological after discontinuing a TNF were enrolled in the nationwide cohort study.

An analysis of data from 4 phase 2/3 studies provides insight into the effects of guselkumab in psoriatic arthritis based on whether or not a person had prior exposure to TNF inhibitor therapy.

Secukinumab therapy was associated with inhibition of joint tenderness and swelling, but high baseline radiographic damage was associated with reduced likelihood of full inhibition.

In this Q&A, Mireia Moreno, MD, discussed the findings of a study that evaluated the influence of HLA-B27 in the phenotypical expression of peripheral spondyloarthritis (pSpA), including psoriatic arthritis, which is the most well-defined pSpA.

An interview segment with Armstrong in which she elaborates on some of the main points made from her presentation on psoriasis treatments.

Patients with psoriatic arthritis who achieve minimal disease activity during the first year of diagnosis are shown to experience better health-related quality of life, improved mental wellbeing, and reduced fatigue.

Although the incidence rates were similar among those treated with TNFi and biologics-naïve patients, patients with psoriatic arthritis had a 35% increased risk when compared with the general population.

Results from the MUST trial reported that ustekinumab monotherapy was just as effective in treating psoriatic arthritis as treatment with ustekinumab plus methotrexate.

A comparative trial of biologic agents suggest IL-17A inhibitors may more significantly improve skin clearance in comorbid patients.

Two methods of identifying patients with axPsA, including an artificial intelligence approach, reported nearly identical outcomes with positive improvement of symptoms of axPsA.

Low levels of disease activity were achieved and increased throughout the study.

Patients with ankylosing spondylitis generally had more favorable outcomes compared to those with psoriasis or psoriatic arthritis.

Dr. Veronica Anwuri discusses how apremilast (Otezla), the first oral, non biologic treatment option for plaque psoriasis can address the systemic pain associated with psoriatic arthritis.

Patients with psoriatic arthritis (PsA) who have elevated interleukin-23 (IL-23) levels have been linked to higher rates of depression, anxiety, and disease activity.

Novartis announces the EC expanded on the approval of secukinumab in EU to include pediatric patients with childhood arthritic conditions: juvenile idiopathic arthritis, enthesitis-related arthritis, and juvenile psoriatic arthritis.

Dr. Philip Mease explains that it's a good time to be treating psoriatic arthritis after results from a clinical trial show that guselkumab provided continuous improvement across measures of health-related quality of life.

With guselkumab, patients with active psoriatic arthritis achieved efficacy that was sustained through a 2 year clinical trial. Results show that the treatment offered continuous improvement across measures of health-related quality of life.

“The differential contribution of IL-6 and IL-17 pathways to the pathogenesis of psoriatic arthritis is not fully understood,” investigators stated.